Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health Corporation announced that its Board of Directors elected John E. Gallina to the Board, effective March 19, 2026. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., where he spent nearly 30 years in senior finance and risk roles.
The Board determined that Gallina is an independent director under New York Stock Exchange rules and the company’s Corporate Governance Guidelines. He was also appointed to CVS Health’s Audit Committee and designated an “audit committee financial expert” under SEC rules.
Gallina currently serves on the Board of Arrive AI Inc., where he chairs the audit committee, and holds board roles at two privately held non-profit organizations. His compensation as a non-employee CVS Health director will align with that of other non-employee directors, prorated based on his start date.
CVS Health EVP, CPO and General Counsel Samrat S. Khichi reported a tax-related share disposition. On the vesting of a restricted stock unit award, 7,886 shares of common stock were surrendered at $79.60 per share to cover withholding taxes. After this transaction, he directly owns 29,775 shares of common stock and holds 25,608 shares of restricted stock.
CVS Health Corp director and President & CEO J. David Joyner reported a routine tax-withholding transaction. On February 28, 2026, he surrendered 1,944 shares of common stock at $79.90 per share to cover taxes due on a vested restricted stock unit award. After this, he directly held 49,996 common shares and 74,534 RSU-based common stock equivalents.
CVS Health Corp filed a Form 13F reporting its institutional holdings. The report lists 9 holdings with a combined market value of $135,316,653. The filing was signed by Michael Motolo, Executive Director in Woonsocket, RI on 02-13-2026.
CVS Health Corporation filed its annual report describing a large, diversified health solutions company built around insurance, pharmacy services and retail care delivery in the U.S.
As of December 31, 2025, CVS operated about 9,000 retail locations, more than 800 MinuteClinics and roughly 1,000 walk‑in and primary care clinics, and filled or managed up to 1.9 billion prescriptions through its Health Services segment and 1.8 billion prescriptions through Pharmacy & Consumer Wellness.
The company reports four segments: Health Care Benefits (Aetna-branded medical, Medicare, Medicaid and related products), Health Services (PBM, specialty, value‑based care and in‑home evaluations), Pharmacy & Consumer Wellness (retail pharmacy and front store), and Corporate/Other. CVS highlights heavy use of technology and AI, quality accreditations, extensive provider networks, value‑based primary care, and a Healthy 2030 impact strategy focused on people, business, community and planet.
CVS Health reported strong 2025 top-line growth but sharply lower GAAP profit due to large one-time charges. Total revenues rose 7.8% to a record $402.1 billion, with fourth-quarter revenue up 8.2% to $105.7 billion.
Full-year GAAP diluted EPS fell to $1.39 from $3.66, mainly driven by a $5.7 billion goodwill impairment in the Health Services segment and about $1.2 billion of legacy litigation charges. By contrast, adjusted EPS increased to $6.75 from $5.42, reflecting stronger underlying operations, especially in Pharmacy & Consumer Wellness. Cash flow from operations was $10.6 billion. For 2026, CVS reaffirmed GAAP EPS guidance of $5.94–$6.14 and adjusted EPS of $7.00–$7.20, but lowered its operating cash flow outlook to at least $9.0 billion from at least $10.0 billion.
CVS Health executive-related trust reports small share purchase. A trust associated with CVS Health EVP and President, Aetna Steven H. Nelson reported an indirect purchase of 24 shares of CVS common stock on 01/23/2025 at $53.7 per share.
The shares were bought by a broker exercising discretion for a separately managed account in the name of a trust for Nelson’s benefit and were not previously reported due to broker error. They were later transferred to a trust for the benefit of Nelson’s spouse, and Nelson disclaims beneficial ownership of these shares.
CVS Health Corp executive Prem S. Shah, EVP and Group President, reported a routine transaction involving CVS common stock. On 01/01/2026, Shah surrendered 247 shares of CVS Health Corp common stock at $80.13 per share, coded as an "F" transaction, which represents shares withheld to pay taxes due upon the settlement of deferred vested stock units. After this tax-related surrender, Shah beneficially owned 61,509.3235 shares of CVS common stock directly, as well as 2,486.5714 deferred stock units awarded under CVS Health’s 2010 and 2017 Incentive Compensation Plans, which he has elected to defer.
CVS Health Corporation furnished information from its 2025 Investor Day, where it discussed strategic priorities and updated its financial outlook. On December 9, 2025, the company issued a press release that revised its full-year 2025 financial guidance and introduced full-year 2026 financial guidance. The press release is attached as Exhibit 99.1 to this report and is incorporated into the Regulation FD disclosure section by reference.
The company notes that this press release and related information are being furnished, not filed, under securities laws, meaning they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
CVS Health Corp executive Tilak Mandadi, EVP and Chief Experience & Technology Officer, reported an automatic share disposition related to equity compensation. On 11/30/2025, he disposed of 6,575 shares of CVS common stock at $80.36 per share. The filing explains this was a surrender of shares to pay withholding taxes due upon the vesting and settlement of a restricted stock unit award, which is a common administrative transaction rather than an open‑market sale. After this tax-related transaction, Mandadi beneficially owned 74,085 CVS shares, held directly.